Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 6/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | GALK1 | P51570 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302514 | 0.93 | PTGES (0.39) | PTGESGRM5EPAS1SORT1RIOK2 | |
| SCHEMBL2355786 | 0.92 | PTGES (0.42) | PTGESGRM5IDH2ALDH1A1GAA | |
| SCHEMBL2302457 | 0.91 | PTGES (0.47) | PTGESGRM5EPAS1SORT1RIOK2 | |
| SCHEMBL2685983 | 0.85 | PTGES (0.41) | PTGESGRM5EPAS1SORT1RIOK2 | |
| SCHEMBL2686563 | 0.84 | PTGES (0.41) | PTGESGRM5EPAS1SORT1BTK | |
| SCHEMBL10173652 | 0.83 | PTGES (0.49) | PTGESGRM5IDH2ALDH1A1GAA | |
| SCHEMBL2357387 | 0.83 | PTGES (0.47) | PTGESGRM5EPAS1SORT1RIOK2 | |
| SCHEMBL10173627 | 0.81 | CNR1 (0.39) | PTGES | |
| SCHEMBL10173657 | 0.81 | PTGES (0.43) | PTGESALDH1A1GAAMEN1KMT2A | |
| SCHEMBL10173628 | 0.79 | PTGES (0.44) | PTGESMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703796-B2 | 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | MAP4, MAPRE2, IL4 | PTGES 132/4885GRM5 2661/4885IDH2 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.